Colorectal cancer
(CRC) is one of the most prevalent forms of cancer that shows a high mortality
and increasing incidence. There are numerous successful treatment options for
CRC, including surgery, chemotherapy, radiotherapy and immunotherapy; however,
their side effects and limitations are considerable. Probiotics may be an
effective strategy for preventing and inhibiting tumour growth through
stimulation of host innate and adaptive immunity. We investigated and COMPARED
potential anti-tumour immune responses induced by two isolated Lactobacillus
strains, Lactobacillus plantarum A and Lactobacillus rhamnosus b, by
pre-inoculating mice with lactobacilli for 14 days. Subsequently, subcutaneous
and orthotopic intestinal tumours were generated in the pre-inoculated mice
using CT26 murine adenocarcinoma cells and were assessed for response against
the tumour. Our results indicated that oral administration with L. plantarum inhibited
CT26 cell growth in BALB/c mice and prolonged the survival time of
tumour-bearing mice compared with mice administered L. rhamnosus. L. plantarum
produced protective immunity against the challenge with CT26 cells by
increasing the effector functions of CD8+ and natural killer (NK) cell
infiltration into tumour tissue, up-regulation of IFN-γ (but not IL-4 or IL-17)
production, and promotion of Th1-type CD4+ T differentiation. Consequently, our
results suggest that L. plantarum can enhance the anti-tumour immune response
and delay tumour formation
Anti-tumour immune
effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing
mice.
No comments:
Post a Comment